Lilly has announced a significant investment of US$1.5 billion in new manufacturing facilities located in North Carolina, Indiana, and Ireland.
These state-of-the-art facilities will play a crucial role in expanding Lilly's production capabilities.
One of the key developments is the establishment of a technologically advanced monoclonal antibody manufacturing plant in Raheen, County Limerick, Ireland.
This facility, set to be completed by 2026, will not only produce existing products but also contribute to the production of Lilly's clinical product pipeline. It is expected to employ approximately 300 specialists from various fields.
In addition to the facility in Ireland, Lilly plans to invest US$1 billion in Concord, USA, to construct new manufacturing facilities for injectable products and devices. This investment is projected to create nearly 600 job opportunities.
By leveraging the skilled manufacturing workforce in the state of Concord and fostering collaborations with renowned research institutions and community colleges with strong STEM programs, Lilly aims to maximize the potential of this site.
Furthermore, Lilly intends to invest US$500 million in Limerick, Ireland, to establish a new biologics active ingredients site, generating over 300 jobs. The company will be hiring scientists, engineers, and production personnel for each facility, ensuring the efficient production and distribution of life-changing medications.
Through these strategic investments, Lilly aims to bolster its biologic active ingredient manufacturing network, meet the growing demand for its existing products, and play a vital role in bringing its extensive pipeline, including its promising neurodegenerative portfolio, to individuals worldwide. The expansion aligns with Lilly's overarching mission of developing medications that enhance people's lives across the globe, focusing on areas such as diabetes, neuro degeneration, cancer, and immunology.
Overall, Lilly's commitment to expanding its manufacturing capabilities reflects its dedication to innovation and meeting the healthcare needs of a wide range of patients.